2018 Presentations

 

Sessions and presentations will be added as permissions are provided.

Presentations are provided in PDF with author's permission. Use the links below to find the session you're looking for. For
presentations that are not provided, contact IMPAACT Operations for contact information.

 

Drop down to presentations:

IMPAACT Plenary

Treatment Scientific Committee

Tuberculosis Scientific Committee

Cure Scientific Committee

Prevention Scientific Committee

Laboratory Center

Other

 

IMPAACT Plenary

Monday, 18 June 2018

Moderators: Sharon Nachman, MD and Grace Aldrovandi, MD

State of the Network

Sharon Nachman, MD

Maternal Isoniazid Preventive Therapy for Tuberculosis (TB) Prevention in High Burden TB/HIV settings: Results of the IMPAACT P1078 Trial

Amita Gupta, MD

Precision Vaccines: Rationale for Early Life Immunization Against HIV Ofer Levy, MD, PhD

NIAID: State of the Institute and Priorities for HIV/AIDS Research

Anthony Fauci, MD

Imaging the Dynamics and Localization of Immune Cells in situ – New Insights and Technologies Useful to the HIV Cure Community

Ronald Germain, MD, PhD

Optimizing the Impact of PEPFAR

Ambassador Deborah Birx, MD

 

Treatment Scientific Committee

Monday, 18 June 2018

Welcome and Overview of Treatment Scientific Agenda

Elaine Abrams and Ted Ruel

Update on Dolutegravir

Overview of Recent Findings on Dolutegravir

Elaine Abrams

Implications of Recent DTG Findings for IMPAACT 2010/VESTED

Lameck Chinula

Panel Discussion: Clinical Implications and Community Perspectives

Moderator: Elaine Abrams

Panelists: Linda Barlow-Mosha, Yuitiang Durier, Maximina Jokonya, Ted Ruel

Treatment Committee Scientific Updates

P1026s, Focus on TAF: Pharmacokinetic Properties of Antiretrovirals Therapy During Pregnancy

Mark Mirochnick


P1093: Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572 (Dolutegravir), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

Ted Ruel


P1101: Phase I/II Dose-Finding, Safety, Tolerance, & PK Study of Raltegravir-Containing ART Regimen in HIV-Infected & TB Co-Infected Children

Paul Krogstad


P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

Adrie Bekker


P1110: A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-Exposed Infants at High Risk

Diana Clarke



Updates on Treatment Studies Enrolling, Pending and In-development

Elaine Abrams and
Ted Ruel

 

Tuberculosis Scientific Committee

Monday, 18 June 2018

Welcome and Overview of Tuberculosis Scientific Agenda

Anneke Hesseling and Amita Gupta

Pediatric Trials for Multidrug-Resistant Tuberculosis

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIVUninfected Infants, Children and Adolescents with MDR-TB Disease

 

Anneke Hesseling

IMPAACT 2005: A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected Children with MDR-TB

 

Ethel Weld

IMPAACT 2020: Shortened Oral Treatment for Multidrug-Resistant Tuberculosis in Infants, Children and Adolescents (SMaRT Kids): A Phase III Randomized Multi-center Trial

Anthony Garcia-Prats

Drug Susceptible TB: Opportunities and Priorities

Tuberculosis Scientific Committee

Lessons Learned and Future Directions for TB Pregnancy Trials

Update and Way Forward for Phase I/II Maternal and Pediatric Prevention Studies:

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-infected Women in High TB Incidence Settings

A5279: One month of Rifapentine/Isoniazid to Prevent TB in People with HIV: BRIEF-TB

 

 

Amita Gupta


IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection

 

Jyoti Mathad

P1026s: Pharmacokinetic Properties of Antiretroviral Therapy during Pregnancy

Jennifer Hughes

TB Pregnancy Registry

Tuberculosis Scientific Committee

Future Opportunities and Priorities for the TB SC

Innovative statistical methods for Phase III Tuberculosis Trials in Children

Soyeon Kim

State of the Art: TB drug pharmacokinetics at the site of disease

Veronique Dartois

Regulatory Perspectives from the FDA on Priorities and Methods for TB Trials in Children and Pregnant Women

Lynne Yao

Roundtable Discussion: Future MDR-TB Trials

Tuberculosis Scientific Committee

 

Cure Scientific Committee

Tuesday, 19 June 2018

Effects of Broadly Neutralizing Antibody Combinations in HIV-1 Infection

Marina Caskey

 

Prevention Scientific Committee Meeting

Tuesday, 19 June 2018

Welcome and Overview of Prevention Scientific Agenda

Lynda Stranix-Chibanda

Prevention of Vertical Transmission of HIV

PROMISE: Progress to date, plans for the future, and gaps remaining for perinatal HIV prevention

Mary Glenn Fowler

Role of Maternal Viral Load in HIV Transmission in Promise

Patricia Flynn

PROMISE Maternal Study of HIV Drug Resistance

Lisa Frenkel

Immune correlates of protection against postnatal HIV-1 transmission among highly-active antiretroviral-treated mothers in the IMPAACT PROMISE study Eliza Hompe

Immune Strategies for Prevention

Use of Non-Human Primates in TB vaccine research

Shelby O’Connor

HIV neutralizing antibody responses in infected children from the IMPAACT repository (NWCS 607) Giny Fouda
Study update: IMPAACT P1112: Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1 Exposed Infants Coleen Cunningham

 

Laboratory Center Presentations

TB Source Book Implementation

Anne-Marie Demers

PROMISE Maternal Study of HIV Drug Resistance

Lisa Frenkel

SDAC's Proposal for PK Results Submission to clinicaltrials.gov

David Shapiro

The Role of Laboratory in TB / Root Cause / Communications

Anne Purfield

Innovative Approaches to EQA

Anne Leach; pSMILE

HAIN LPA

Derek Armstrong

Web-based Pharmacology Tutorial

Robin Difrancesco

Regulatory Inspection Readiness for Laboratories

Ed Acosta

External Data Transfers to the DMC

Heather Sprenger

 

Other Presentations

Audit/Inspection Readiness (PPD)

Barbara Petrie and Teri Andresen


 

 

 

 

 

 

 

 

 

 

 


 

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.